Table 3.
Day 60 model | Day 90 model | Day 120 model | |
Antihyperlipidemics | |||
Sensitivity | 89.9% | 90.0% | 90.0% |
Specificity | 44.8% | 75.8% | 82.0% |
Accuracy | 46.2% | 76.2% | 82.2% |
Positive predictive value | 44.8% | 75.8% | 82.0% |
Negative predictive value | 99.3% | 99.6% | 99.6% |
Antihypertensives | |||
Sensitivity | 90.0% | 90.0% | 90.0% |
Specificity | 36.9% | 68.0% | 80.7% |
Accuracy | 38.3% | 68.6% | 80.9% |
Positive predictive value | 36.9% | 68.0% | 80.7% |
Negative predictive value | 99.3% | 99.6% | 99.7% |
Oral hypoglycemics | |||
Sensitivity | 90.0% | 90.0% | 90.0% |
Specificity | 46.8% | 72.6% | 81.4% |
Accuracy | 48.3% | 73.2% | 81.7% |
Positive predictive value | 46.8% | 72.6% | 81.4% |
Negative predictive value | 99.2% | 99.5% | 99.5% |
All metrics improved across the three prediction dates.